The price of olverembatinib is affected by factors including specifications, regions and medical insurance policies. Currently, the reference price range for one box (approximately 20-40 tablets) is between USD1500 and USD 4500 The exact price shall be subject to the actual pricing of medical institutions or licensed pharmacies. As a prescription-targeted therapy drug, it must be used strictly in accordance with the doctor’s advice, and shall not be purchased or dosed without authorization.
Key Information Notes
1. Factors Affecting the Price
Drug Specifications
Different tablet counts or dosage specifications directly affect the price.
Regional Differences
Variations in procurement channels, transportation costs and policy subsidies across different regions may lead to price fluctuations.
Medical Insurance Reimbursement
Medical insurance or specific insurance plans in some regions may cover part of the expenses. Please consult the local medical insurance authority for details.
Access Methods
The drug can only be purchased at hospitals or designated pharmacies with a doctor’s prescription. Avoid obtaining it through informal channels.
Eligible patients may participate in pharmaceutical company assistance programs or charitable drug donation schemes to alleviate financial burden.
Medication Precautions
This drug is indicated for the treatment of specific types of leukemia (e.g., T315I-mutated chronic myeloid leukemia), and its applicability must be confirmed through genetic testing.
During the treatment period, it is necessary to regularly monitor indicators such as blood routine and liver function, and adjust the treatment plan as advised by the doctor.
Common side effects include thrombocytopenia, anemia and edema. Immediate medical attention is required if severe adverse reactions occur.
Medical Consultation Guidelines
Prior to the administration of olverembatinib, patients must be evaluated by hematology or oncology specialists to formulate an individualized treatment plan. Close communication with the attending doctor should be maintained during the treatment course, and the medication must not be discontinued or adjusted without authorization. For patients under significant financial pressure, consult hospital social workers or relevant public welfare organizations for information on financial support programs.
